Related Experiment Videos
Chlamydia pneumoniae and Mycoplasma pneumoniae.
Francesco Blasi1, P Tarsia, S Aliberti
1Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Ospedale Maggiore Milano, Milan, Italy. francesco.blasi@unimi.it
Seminars in Respiratory and Critical Care Medicine
|January 3, 2006
Summary
Mycoplasma pneumoniae and Chlamydia pneumoniae are common causes of community-acquired pneumonia (CAP) in young people. Enzyme immunoassays and microimmunofluorescence are key diagnostic tools, with various antibiotics showing effectiveness against these infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pulmonology
Background:
- Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) globally, particularly in individuals aged 5-20.
- Chlamydia pneumoniae contributes to 6-20% of CAP cases, with prevalence varying by population, age, and diagnostic methods.
Purpose of the Study:
- To review diagnostic methods and treatments for Mycoplasma pneumoniae and Chlamydia pneumoniae infections causing CAP.
- To highlight the efficacy of various antimicrobial agents against these common respiratory pathogens.
Main Methods:
- Enzyme immunoassay (EIA) for Mycoplasma pneumoniae diagnosis, offering IgG and IgM titration with high sensitivity (92%) and specificity (95%) on paired samples.
- Microimmunofluorescence testing as the gold standard for serological diagnosis of Chlamydia pneumoniae acute infection.
Main Results:
- EIA demonstrates reliable diagnostic performance for Mycoplasma pneumoniae.
- Tetracyclines and macrolides (like erythromycin) are effective against Chlamydia pneumoniae.
- A broad spectrum of antimicrobials, including tetracyclines, macrolides, ketolides, lincosamides, streptogamines, chloramphenicol, and fluoroquinolones, show potential activity against Mycoplasma pneumoniae.
Conclusions:
- Accurate diagnosis of Mycoplasma pneumoniae and Chlamydia pneumoniae is crucial for effective CAP management.
- Established and novel antimicrobial agents offer various treatment options for these bacterial pneumonias.